Detection and staging of recurrent or metastatic nasopharyngeal carcinoma in the era of FDG PET/MR

Eur Arch Otorhinolaryngol. 2022 Jan;279(1):353-359. doi: 10.1007/s00405-021-06779-5. Epub 2021 Mar 29.

Abstract

Purpose: The aim of this pilot study was to evaluate the accuracy of 18 fluorodeoxyglucose (FDG) PET/MR imaging in detection and staging of recurrent or metastatic NPC.

Patients and methods: The PET/MR scans of 60 patients with clinically diagnosed recurrent or metastatic NPC between April 2017 and November 2019 were included in this study. Findings were evaluated according to the eighth edition of the American Joint Committee on Cancer staging system. Final diagnosis was confirmed at biopsy or imaging follow-up for at least 6 months.

Results: Of the 60 patients, 25, 26 and 42 had developed local lesions, regional nodal metastases and distant metastases, respectively. The overall accuracy of PET/MR imaging for staging of recurrent or metastatic NPC was 88.3%.

Conclusions: For recurrent or metastatic NPC, 18 FDG PET/MRI might serve as a single-step staging modality.

Keywords: Metastatic; Nasopharyngeal carcinoma; PET/MR; Recurrent; Staging.

MeSH terms

  • Fluorodeoxyglucose F18*
  • Humans
  • Magnetic Resonance Imaging
  • Nasopharyngeal Carcinoma / diagnostic imaging
  • Nasopharyngeal Neoplasms* / diagnostic imaging
  • Nasopharyngeal Neoplasms* / pathology
  • Neoplasm Recurrence, Local / diagnostic imaging
  • Neoplasm Staging
  • Pilot Projects
  • Positron-Emission Tomography
  • Radiopharmaceuticals
  • Sensitivity and Specificity

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18